A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.

[1]  A. Clark,et al.  The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates , 2020, Journal of aerosol medicine and pulmonary drug delivery.

[2]  P. D’Andrea,et al.  Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings , 2019, Airway pharmacology and treatment.

[3]  M. Cabana,et al.  Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations , 2018, The New England journal of medicine.

[4]  I. Pavord,et al.  Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations , 2018, The New England journal of medicine.

[5]  P. Bardin.  Escalating Inhaled Glucocorticoids to Prevent Asthma Exacerbations. , 2018, The New England journal of medicine.

[6]  Y. Nakano,et al.  Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices , 2018, PloS one.

[7]  M. Miravitlles,et al.  Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus , 2017, COPD.

[8]  S. Khindri,et al.  Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects. , 2016, Pulmonary pharmacology & therapeutics.

[9]  H. Chan,et al.  Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  P. Chanez,et al.  Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination. , 2013, Pulmonary pharmacology & therapeutics.

[11]  M. Hibbs,et al.  Identification of pathogenic macrophage subpopulations in lung disease , 2012 .

[12]  Thomas M. Smith,et al.  Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects , 2012 .

[13]  D. Ziegler,et al.  Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol , 2010, Current medical research and opinion.

[14]  J. Karpel,et al.  Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma , 2007, Current medical research and opinion.

[15]  Linda Abetz,et al.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. , 2006, Respiratory medicine.

[16]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[17]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[18]  S. Li,et al.  Drug delivery performance of the mometasone furoate dry powder inhaler. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[19]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[20]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .